PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.89
Current Ratio below 0.5x Biotechnology median of 4.13. Jim Chanos might see a looming risk of liquidity crunch.
1.89
Quick Ratio below 0.5x Biotechnology median of 4.11. Jim Chanos might see a liquidity gap if the firm cannot tap more credit swiftly.
1.73
Cash Ratio 0.75–0.9x Biotechnology median of 2.30. John Neff could push for improved balance sheet strength.
No Data
No Data available this quarter, please select a different quarter.
-13.15
Negative short-term coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize cash flow quality and look for immediate refinancing solutions.